Elucidation of Teicoplanin Interactions with Drug Targets Related to COVID-19

Teicoplanin is a glycopeptide antibiotic effective against several bacterial infections, has exhibited promising therapeutic efficiency against COVID-19 in vitro, and the rationale for its use in COVID-19 is yet to be recognized. Hence, in this study a number of molecular modeling techniques were employed to decrypt the mechanistic insight of teicoplanin interaction with several COVID-19 drug targets. Initially, molecular docking was employed to study the teicoplanin interaction with twenty-five SARS-CoV-2 structural and non-structural proteins which was followed by molecular mechanics/generalized Born surface area (MM/GBSA) computation for binding energy predictions of top ten models from each target. Amongst all macromolecular targets, the N-terminal domain of the nucleocapsid protein displayed the strongest affinity with teicoplanin showing binding energies of -7.4 and -102.13 kcal/mol, in docking and Prime MM/GBSA, respectively. Thermodynamic stability of the teicoplanin-nucleocapsid protein was further probed by molecular dynamics simulations of protein-ligand complex as well as unbounded protein in 100 ns trajectories. Post-simulation MM-GBSA computation of 50 frames extracted from simulated trajectories estimated an average binding energy of -62.52 +/- 12.22 kcal/mol. In addition, conformational state of protein in complex with docked teicoplanin displayed stable root-mean-square deviation/fluctuation. In conclusion, computational investigation of the potential targets of COVID-19 and their interaction mechanism with teicoplanin can guide the design of novel therapeutic armamentarium for the treatment of SARS-CoV-2 infection. However, additional studies are warranted to establish the clinical use or relapses, if any, of teicoplanin in the therapeutic management of COVID-19 patients.

Automated summary

Teicoplanin, a glycopeptide antibiotic, has shown promising therapeutic efficacy against COVID-19 in vitro. This study utilized molecular modeling techniques to investigate its interaction with various COVID-19 drug targets, with the N-terminal domain of the nucleocapsid protein displaying the strongest affinity. Molecular dynamics simulations and MM-GBSA computations revealed stable binding energies between teicoplanin and the nucleocapsid protein, suggesting its potential as a therapeutic agent for SARS-CoV-2 infection. Additional studies are needed to confirm its clinical use in COVID-19 management.